BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32418825)

  • 1. Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.
    Zhang YJ; Li H; Zhong R; Chen W; Kou G; Liu G; Cheng Y
    Clin Lung Cancer; 2020 Sep; 21(5):e493-e496. PubMed ID: 32418825
    [No Abstract]   [Full Text] [Related]  

  • 2. Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M.
    Senoo S; Ohashi K; Nishii K; Hara N; Kano H; Ninomiya K; Maeda Y; Kiura K
    J Thorac Oncol; 2018 Aug; 13(8):e140-e142. PubMed ID: 30049375
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Okuno T; Arakawa S; Yoshida T; Ohe Y
    Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
    [No Abstract]   [Full Text] [Related]  

  • 4. Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.
    Schmid S; Stewart EL; Martins-Filho SN; Cabanero M; Wang A; Bao H; Wu X; Patel D; Chen Z; Law JH; Bradbury PA; Shepherd FA; Leighl N; Tsao MS; Pugh T; Bratman SV; Sacher A; Liu G
    Clin Lung Cancer; 2020 Sep; 21(5):e488-e492. PubMed ID: 32389504
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.
    Grolleau E; Haddad V; Boissière L; Falchero L; Arpin D
    J Thorac Oncol; 2019 Jul; 14(7):e151-e153. PubMed ID: 31235042
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.
    Théoleyre S; Masson I; Herbreteau G; Vallée A; Sénellart H; Denis MG
    Lung Cancer; 2017 Dec; 114():111-112. PubMed ID: 29096978
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
    Yoshida H; Ooi M; Kim YH
    J Thorac Oncol; 2018 Nov; 13(11):e219-e220. PubMed ID: 30368410
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
    Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
    Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
    Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
    Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
    Yang X; Huang C; Chen R; Zhao J
    Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
    [No Abstract]   [Full Text] [Related]  

  • 11. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
    Gortais H; Daniel C; Bidard FC; Jeannot E; Callens C; Cabel L
    J Thorac Oncol; 2017 Sep; 12(9):e138-e139. PubMed ID: 28838712
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
    Chiang CL; Yeh YC; Chou TY; Chiu CH
    J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232
    [No Abstract]   [Full Text] [Related]  

  • 15. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
    Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
    Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic value of cerebrospinal fluid ctDNA detection by next-generation sequencing for meningeal carcinomatosis: a case report.
    Guo X; Cui J; Zhao Y; Han W; Zou Y; Gao R; Li Q; Li X; He J; Bu H
    BMC Neurol; 2019 Mar; 19(1):38. PubMed ID: 30851728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.